1-4 of 4
Hans Juergen Kuehnel
Close
Sort by
Journal Articles

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Wing H. Tong, MD, Rob Pieters, Gertjan Kaspers, MD, PhD, Maroeska D.W.M. te Loo, MD, PhD, Marc Bierings, Cor van den Bos, MD, PhD, Wouter J.W. Kollen, MD, PhD, Wim C.J. Hop, PhD, Joachim Boos, MD, PhD, Mary V. Relling, PharmD, Hans Juergen Kuehnel, MD, Wim J Tissing, MD, PhD, Inge M. van der Sluis, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2634.
https://doi.org/10.1182/blood.V122.21.2634.2634
Published: 2013
Journal Articles

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Caroline YK Fong, Catriona Anne Parker, Adiba Hussain, Jizhong Liu, Monika Essink, Hans Juergen Kuehnel, Donna L Lancaster, Genevieve Pridham, Debbie Payne, Charlotte O'Horo, Shekhar Krishnan, Jeremy Hancock, Nicholas Goulden, Anthony V. Moorman, Sue Richards, Ajay J Vora, Vaskar Saha, Ashish Narayan Masurekar
Journal: Blood
Blood (2011) 118 (21): 2573.
https://doi.org/10.1182/blood.V118.21.2573.2573
Published: 2011
Journal Articles

Population Pharmacokinetic of Native Escherichia Coli Asparaginase.

Stephan Borghorst, Rob Pieters, Hans Juergen Kuehnel, Joachim Boos, Georg Hempel
Journal: Blood
Blood (2009) 114 (22): 4803.
https://doi.org/10.1182/blood.V114.22.4803.4803
Published: 2009
Journal Articles

Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial

Clinical Trials & Observations
Rob Pieters, Inge Appel, Hans-Juergen Kuehnel, Iris Tetzlaff-Fohr, Uwe Pichlmeier, Inekee van der Vaart, Eline Visser, Rolinda Stigter
Journal: Blood
Blood (2008) 112 (13): 4832–4838.
https://doi.org/10.1182/blood-2008-04-149443
Published: 2008